Close Menu

NEW YORK (360Dx) – Qiagen announced today that the US Food and Drug Administration approved the company's test for assessing the risk of spontaneous preterm birth in patients with preterm labor symptoms.

PartoSure includes a noninvasive strip test that detects placental alpha microglobulin in patients. It provides results in five minutes or less, and, said Qiagen, studies have demonstrated that, compared with current diagnostic methods, the test has a higher positive predictive value for preterm birth while maintaining an equally high negative predictive value.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.